Statements (46)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
anxiolytic drug |
| gptkbp:approvedBy |
gptkb:Russia
|
| gptkbp:ATCCode |
N05BX
|
| gptkbp:brand |
gptkb:Afobazol
|
| gptkbp:CASNumber |
173352-39-1
|
| gptkbp:chemicalClass |
5-ethoxy-2-[2-(morpholino)ethylthio]benzimidazole dihydrochloride
|
| gptkbp:compatibleWith |
gptkb:European_Union
gptkb:United_States muscle relaxation benzodiazepine sedation antidepressant dependence |
| gptkbp:contraindication |
pregnancy
lactation children under 18 |
| gptkbp:developedBy |
gptkb:Russia
|
| gptkbp:discoveredBy |
Russian scientists
|
| gptkbp:form |
tablets
|
| gptkbp:hasNo |
international nonproprietary name (INN)
|
| https://www.w3.org/2000/01/rdf-schema#label |
Afobazol
|
| gptkbp:legalStatus |
prescription only (Russia)
|
| gptkbp:marketedAs |
2001
OTCPharm |
| gptkbp:mechanismOfAction |
modulation of GABA receptors
modulation of sigma-1 receptors selective anxiolytic effect |
| gptkbp:notControlledSubstance |
gptkb:Russia
most countries |
| gptkbp:prescriptionStatus |
prescription only (Russia)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
headache
allergic reactions gastrointestinal upset |
| gptkbp:usedFor |
gptkb:adjustment_disorder
gptkb:alcohol_withdrawal_syndrome gptkb:generalized_anxiety_disorder sleep disorders smoking cessation anxiety disorders neurasthenia asthenic disorders somatic disorders |
| gptkbp:bfsParent |
gptkb:Pharmstandard
|
| gptkbp:bfsLayer |
8
|